Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Liabilities and Shareholders Equity (2016 - 2026)

Heron Therapeutics filings provide 16 years of Liabilities and Shareholders Equity readings, the most recent being $246.2 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 4.44% to $246.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $983.1 million, a 8.3% increase, with the full-year FY2025 number at $255.9 million, up 9.75% from a year prior.
  • Liabilities and Shareholders Equity hit $246.2 million in Q1 2026 for Heron Therapeutics, down from $255.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $273.7 million in Q1 2022 to a low of $201.2 million in Q2 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $233.1 million (2024), compared with a mean of $236.7 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 39.65% in 2022 and later rose 12.76% in 2025.
  • Heron Therapeutics' Liabilities and Shareholders Equity stood at $251.0 million in 2022, then decreased by 11.33% to $222.5 million in 2023, then grew by 4.78% to $233.1 million in 2024, then grew by 9.75% to $255.9 million in 2025, then dropped by 3.78% to $246.2 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $246.2 million (Q1 2026), $255.9 million (Q4 2025), and $249.0 million (Q3 2025) per Business Quant data.